Short Interest in PURE Bioscience (OTCMKTS:PURE) Rises By 191.0%

PURE Bioscience (OTCMKTS:PURE) saw a significant increase in short interest in June. As of June 30th, there was short interest totaling 11,031 shares, an increase of 191.0% from the June 15th total of 3,791 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 30,287 shares, the days-to-cover ratio is currently 0.4 days.

PURE Bioscience Trading Down 4.1%

PURE Bioscience stock traded down $0.00 during mid-day trading on Tuesday, hitting $0.06. The company had a trading volume of 4,075 shares, compared to its average volume of 32,764. PURE Bioscience has a 12-month low of $0.04 and a 12-month high of $0.14. The company’s fifty day moving average is $0.07 and its 200-day moving average is $0.06. The company has a market capitalization of $8.23 million, a price-to-earnings ratio of -2.11 and a beta of 0.22.

PURE Bioscience (OTCMKTS:PURE) last issued its quarterly earnings data on Monday, June 15th. The company reported ($0.01) EPS for the quarter. The firm had revenue of $0.51 million for the quarter.

PURE Bioscience Company Profile

PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions.